TRCT
PPH icon

Tower Research Capital (TRC)’s VanEck Pharmaceutical ETF PPH Stock Holding History

Tower Research Capital (TRC)’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$31.6M Buy
304,499
+295,748
+3,380% +$31.5M 0.82% 12
2025
Q4 		$903K Sell
8,751
-13,076
-60% -$1.27M 0.02% 545
2025
Q3 		$1.97M Sell
21,827
-12,797
-37% -$1.12M 0.05% 296
2025
Q2 		$3.05M Buy
34,624
+34,614
+346,140% +$3M 0.08% 224
2025
Q1 		$911 Sell
10
-34,541
-100% -$3.11M ﹤0.01% 4804
2024
Q4 		$2.98M Buy
34,551
+5,313
+18% +$481K 0.06% 259
2024
Q3 		$2.78M Buy
+29,238
New +$2.78M 0.07% 191
2024
Q2 		– Sell
-3,585
Closed -$325K – 5937
2024
Q1 		$325K Sell
3,585
-19,141
-84% -$1.68M 0.01% 1111
2023
Q4 		$1.85M Buy
22,726
+6,232
+38% +$489K 0.02% 539
2023
Q3 		$1.32M Buy
16,494
+8,975
+119% +$724K 0.04% 435
2023
Q2 		$592K Sell
7,519
-22,048
-75% -$1.73M 0.02% 864
2023
Q1 		$2.29M Buy
+29,567
New +$2.28M 0.07% 170
2022
Q4 		– Sell
-51,808
Closed -$3.48M – 6254
2022
Q3 		$3.48M Buy
51,808
+46,978
+973% +$3.46M 0.06% 270
2022
Q2 		$371K Buy
+4,830
New +$377K 0.01% 1326
2022
Q1 		– Sell
-7,641
Closed -$588K – 6455
2021
Q4 		$588K Sell
7,641
-10,162
-57% -$756K 0.01% 1004
2021
Q3 		$1.3M Sell
17,803
-11,877
-40% -$886K 0.03% 406
2021
Q2 		$2.17M Buy
29,680
+16,562
+126% +$1.18M 0.06% 279
2021
Q1 		$905K Buy
13,118
+12,145
+1,248% +$837K 0.02% 831
2020
Q4 		$65K Buy
973
+466
+92% +$29.9K ﹤0.01% 2825
2020
Q3 		$32K Sell
507
-12,783
-96% -$808K ﹤0.01% 3705
2020
Q2 		$827K Buy
+13,290
New +$804K 0.03% 648
2020
Q1 		– Sell
-13,927
Closed -$893K – 3704
2019
Q4 		$893K Buy
13,927
+12,365
+792% +$745K 0.07% 137
2019
Q3 		$89K Sell
1,562
-40,426
-96% -$2.32M 0.01% 1426
2019
Q2 		$2.46M Buy
41,988
+30,642
+270% +$1.77M 0.17% 84
2019
Q1 		$689K Buy
11,346
+5,768
+103% +$341K 0.04% 427
2018
Q4 		$305K Buy
5,578
+1,644
+42% +$99.6K 0.02% 565
2018
Q3 		$253K Sell
3,934
-23,306
-86% -$1.45M 0.02% 842
2018
Q2 		$1.61M Buy
27,240
+8,860
+48% +$514K 0.09% 208
2018
Q1 		$1.04M Sell
18,380
-12,106
-40% -$723K 0.09% 184
2017
Q4 		$1.81M Buy
30,486
+30,014
+6,359% +$1.72M 0.23% 87
2017
Q3 		$27K Sell
472
-16,116
-97% -$915K ﹤0.01% 2527
2017
Q2 		$980K Buy
16,588
+16,290
+5,466% +$922K 0.11% 140
2017
Q1 		$16K Buy
298
+131
+78% +$7.11K ﹤0.01% 1438
2016
Q4 		$9K Sell
167
-275
-62% -$14.7K ﹤0.01% 2724
2016
Q3 		$25K Buy
+442
New +$26.5K ﹤0.01% 1490

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return
ERSOT
Employees Retirement System of Texas Austin, Texas $11.4B AUM 21.6% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
JSAM
J. Safra Asset Management New York $1.86B AUM 22.95% 1-Year Est. Return
AT
Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Tower Research Capital (TRC)'s PPH Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its VanEck Pharmaceutical ETF (PPH) stake by 3,380% in Q1 2026, buying an estimated $31.5M and bringing the position to 304,499 shares worth $31.6M. The position accounts for 0.82% of the portfolio, ranked #12.

Tower Research Capital (TRC) first reported a position in PPH in Q3 2016 and has held it in 35 quarters since. 147 funds tracked by Wall St. Rank hold PPH as of Q1 2026.

  • Tower Research Capital (TRC) held 304,499 shares of VanEck Pharmaceutical ETF worth $31.6M as of Q1 2026.
  • Tower Research Capital (TRC) bought 295,748 VanEck Pharmaceutical ETF shares in Q1 2026, an estimated $31.5M.
  • VanEck Pharmaceutical ETF made up 0.82% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #12 holding.
  • Tower Research Capital (TRC) first reported a position in VanEck Pharmaceutical ETF in Q3 2016 and has held it in 35 quarters since.
  • 147 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.